MOTS-c is a 16-amino-acid peptide produced by mitochondria, the energy-generating structures inside your cells. Unlike most proteins in the body, which are coded by DNA in the cell’s nucleus, MOTS-c is encoded within the mitochondrial genome, specifically within a gene called the 12S rRNA. That distinction makes it part of a small, recently discovered class of signaling molecules called mitochondrial-derived peptides. First identified in 2015 by researchers at the University of Southern California, MOTS-c has drawn significant attention for its effects on metabolism, insulin sensitivity, and physical performance in animal studies, and it’s now entering early human trials.
How Mitochondria Use MOTS-c to Regulate Metabolism
For decades, mitochondria were understood mainly as cellular power plants, converting food into usable energy. The discovery of MOTS-c changed that picture. It showed that mitochondria also act as signaling hubs, releasing peptides that travel through the bloodstream and influence distant organs. MOTS-c’s primary target appears to be skeletal muscle, where it activates a key energy-sensing enzyme called AMPK.
AMPK functions like a fuel gauge for your cells. When energy runs low, AMPK switches on pathways that burn fat and sugar for fuel while dialing down energy-consuming processes like fat storage. MOTS-c triggers this same switch. Research published in Cell Metabolism showed that MOTS-c works by disrupting the folate cycle, a metabolic process tied to building new DNA components. That disruption activates AMPK, which in turn improves how cells take in and use glucose. It also enhances mitochondrial performance through a pathway involving a protein (PGC-1α) that drives the creation of new, healthier mitochondria inside muscle cells.
Effects on Insulin Sensitivity and Weight
In mouse studies, MOTS-c treatment prevented both age-related and diet-induced insulin resistance. Mice fed a high-fat diet and treated with MOTS-c gained markedly less weight than untreated mice on the same diet, and they maintained better blood sugar control. These findings suggest the peptide helps the body process glucose more efficiently and resist the metabolic damage that comes with excess calories and aging.
A Phase 2 clinical trial is currently recruiting 120 adults with prediabetes and overweight or obesity to test whether 12 weeks of MOTS-c treatment improves insulin sensitivity compared to a placebo. The study is measuring changes in blood sugar markers including fasting glucose and HbA1c (a measure of average blood sugar over several months), along with safety data. This is the first rigorous human trial of the peptide, so clinical evidence in people is still forthcoming.
MOTS-c and Exercise Performance
One of the most striking findings about MOTS-c is how closely it mirrors the metabolic effects of exercise. During physical activity, MOTS-c levels in muscle cells increase nearly 12-fold. Blood levels rise by roughly 50% during and after exercise before returning to baseline after rest. The peptide appears to be part of the molecular machinery that makes exercise beneficial.
When researchers at USC gave MOTS-c to older mice (the human equivalent of 65 and older), the treated animals doubled their running capacity on a treadmill and even outperformed untreated middle-aged mice. Late-life treatment also improved grip strength, stride length, and walking performance. Younger and middle-aged mice showed similar gains in balance on a rotating rod and endurance on an accelerating treadmill. Even mice on a high-fat diet showed marked physical improvement after treatment. These results have led some researchers to describe MOTS-c as an “exercise mimetic,” a compound that reproduces some of the body’s responses to physical activity.
Why MOTS-c Declines With Age
Mitochondrial function deteriorates as you get older, and MOTS-c production appears to follow that decline. Lower levels of the peptide track with the metabolic changes common in aging: rising insulin resistance, loss of muscle mass, and reduced exercise capacity. The mouse studies showing that MOTS-c treatment can reverse age-related insulin resistance and restore physical performance suggest the peptide’s decline may be more than a passive marker of aging. It may actively contribute to the metabolic problems that accumulate over time.
Safety and Side Effects
Because MOTS-c is a peptide the body already produces, it carries some theoretical safety advantages over synthetic drugs. It is unlikely to trigger an immune response, and at appropriate concentrations, off-target effects are not expected. Oral forms could cause gastrointestinal discomfort, but that’s a generic issue with oral peptide delivery rather than something specific to MOTS-c. The Phase 2 trial is tracking adverse events and immune reactions over 16 weeks, which will provide the first controlled safety data in humans.
That said, nearly all published evidence comes from mice. The peptide has not been proven safe or effective in people through completed clinical trials.
Regulatory Status
MOTS-c is not approved by the FDA for any use in humans. The FDA has specifically classified it among peptides that cannot lawfully be used in compounded medications, which are custom-mixed drugs prepared by specialty pharmacies. Despite this, MOTS-c is available through some wellness and anti-aging clinics, typically administered as subcutaneous injections.
For athletes, the peptide is prohibited at all times under the World Anti-Doping Agency’s banned substance list. It falls under the category of metabolic modulators, specifically as an activator of AMPK. Any competitive athlete using MOTS-c risks a doping violation regardless of the sport or testing period.
How MOTS-c Is Typically Used
Outside of clinical trials, protocols promoted by wellness providers generally involve subcutaneous injections into the abdomen. One commonly cited protocol uses 5 mg per injection, administered once every five days for a total of four injections over a 20-day cycle, followed by a rest period of at least four months before repeating. Injections are typically timed at night, at least two hours after eating, based on the idea that this aligns with the body’s overnight metabolic repair processes. No more than three cycles per year are generally recommended.
These protocols are based on extrapolation from animal research and clinical reasoning rather than completed human trials. The Phase 2 trial currently underway will be the first to generate controlled dosing and efficacy data in people.